Introduction
First described by Martin et al. (1976) , sigma (s) binding sites were postulated to be new opioid receptor subtypes. Now, it is established that these sites are distinct from any other known receptor. Based on biochemical studies, it is generally accepted that at least two dierent subtypes of s receptors exist, termed sigma-1 (s 1 ) and sigma-2 (s 2 ). The ®rst one shows high anity for benzomorphans, a stereoselectivity for the (+)-isomers, and is usually labelled with the radioligand [ 3 H](+)-pentazocine (DeHaven-Hudkins et al., 1992; Cagnotto et al., 1994) whereas the second exhibits a lower anity for (+)-pentazocine and a reverse stereoselectivity. Usually s 2 binding sites are probed with 1,3-di(2-tolyl)guanidine (DTG) which binds to both subtypes 1 and 2 in roughly equal amounts.
Whatever their subtypes, s receptors were shown to bind a variety of compounds belonging to dierent chemical and pharmacological classes including cytochrome P450 inhibitors, Ca 2+ channel antagonists, antipsychotic and anticonvulsant agents, cocaine and steroids. Among these hormones, progesterone is considered as a possible, although controversial, endogenous ligand (Su et al., 1988; Schwarz et al., 1989; Bergeron et al., 1999) . It appears to be the more potent inhibitor of [ 3 H](+)-pentazocine binding in in vitro studies and a close relationship between steroids and the s 1 receptor subtype was established in dierent physiological and behavioural tests (Maurice et al., 1999) .
s Receptors are expressed in various areas of the brain but also in peripheral organs including liver, testis, kidney, spleen and intestine. Subcellular distribution studies indicated that s 1 receptors are highly concentrated and mainly located on microsomal and plasma membranes (McCann & Su, 1990) , but some studies also suggest that they could be associated with other organelles of the cell (McCann et al., 1994; Dehaven-Hudkins et al., 1994) .
Extensive studies have been performed to elucidate the role of these receptors. The s 1 subtype has been the most studied and characterized. Although this receptor was recently cloned (Hanner et al., 1996) , no clear biological functions have yet been attributed to it. It has been suggested that it modulates several neurotransmitter systems (Maurice et al., 1999) and that it is involved both in CNS pathologies such as schizophrenia, dementia, depression and peripheral nervous system diseases (Pascaud et al., 1990; Matsuno & Mita, 1998; Bowen, 2000) . s, especially s 1 , receptor ligands were also shown to possess anti-ischaemic properties (Matsuno & Mita, 1998; Harukuni et al., 2000) and be eective neuroprotective agents in dierent in vitro and in vivo models tested (Maurice & Lockhart, 1997) .
The reported role of s 1 binding sites in ischaemia brought our interest to this protein. We recently evidenced antiischaemic eects of trimetazidine on various experimental models and observed that these eects were related to a preservation of main mitochondrial functions both in brain and liver of the rat Zini et al., 1996) . It was also shown that [ 3 H]-trimetazidine speci®cally bound to mitochondrial membranes but these binding sites have not been yet identi®ed 2000) . Interestingly, among the drugs able to inhibit [ 3 H]-trimetazidine binding, s ligands competed with high anity (Morin et al., 2000) . Thus the hypothesis was raised that trimetazidine binding sites might be related to s receptors.
In this study, we demonstrate the presence of s 1 like binding sites on puri®ed mitochondria from rat brain and liver, using 
Methods
Preparation of purified rat liver and brain mitochondria Rat brain mitochondria were isolated by dierential centrifugation and puri®ed on a Percoll gradient according to Sims (1990) . Male Wistar rats weighing approximately 250 to 300 g were decapitated. Brains were removed, sliced and washed in a buer containing (mM): sucrose 320, 2-amino-2-hydroxymethyl-propan-1,3-diol (Tris) 10 and ethylenediaminetetracetic acid (EDTA) 1, pH 7.4 at 48C. The brains were then homogenized in 10 ml per g of tissue of the same buer and centrifuged 3 min at 13306g (Sorvall 1 RC 28 S). The supernatants (S 1 ) were kept on ice and the pellets were suspended in 5 ml per g of tissue of the same buer and centrifuged at 13306g for 3 min. The pellets were discarded, the supernatants S 2 pooled to S 1 and centrifuged at 21 2006g for 10 min. The resulting supernatants (S 3 ) were kept on ice. The ®nal pellets were suspended in 15% (v v 71 ) percoll (10 ml g 71 of tissue originally homogenized) and layered on a discontinuous density gradient of 3.5 ml each of 23 and 40% percoll. The tubes were centrifuged at 30 7006g for 5 min. The puri®ed mitochondrial rings were recovered at the interface of the 23 ± 40% fractions using a Pasteur pipette and rinsed in the isolation buer. Microsomal fractions were obtained by centrifugating the supernatants S 3 at 100 0006g for 60 min. Protein contents were determined by the method of Lowry et al. (1951) .
Puri®ed rat liver mitochondria were obtained as previously described . Brie¯y, the livers were excised rapidly and placed in a medium containing (mM): sucrose 250, Tris 50 and ethylene glycol-bis(b-amino ethyl ether) tetraacetic acid (EGTA) 5, pH 7.8 at 48C. Tissue samples (28 g) were minced and homogenized (10 g tissue in 60 ml medium) on ice using a Te¯on Potter homogenizer. The homogenates were centrifuged at 6006g for 10 min (Sorvall 1 RC 28 S) and the supernatants were centrifuged for 10 min at 33006g to obtain mitochondrial pellets. The resulting pellets were washed with medium from which EGTA was omitted and centrifuged for 10 min at 33006g. The ®nal pellets were suspended in 36 ml of Tris-sucrose buer (without EGTA) and mitochondria were puri®ed on a discontinuous sucrose gradient according to Morin et al. (1998) .
The supernatant (from 10 min at 33006g) was centrifuged at 15 0006g for 10 min and then at 170 0006g for 1 h (Sorvall 1 A841 rotor) to obtain a pellet corresponding to thè microsomal fraction'.
All animal procedures used in this study are in strict accordance with the European Community Council Directive of 24 November 1986 (86-609/EEC) and Decree of 20 October 1987 (87-848/EEC).
Preparation of synaptosomal membranes
Male Wistar rats were killed by decapitation, their brains were removed and rapidly dissected. The cerebral cortex was homogenized in 20 volumes of ice-cold sucrose buer (TrisHCl 50 mM, sucrose 0.32 M, pH=7.4 at 48C) using a Te¯on Potter homogenizer. The homogenate was centrifuged at 10006g for 10 min and the pellet was discarded. The supernatant was centrifuged at 50,0006g for 20 min and the supernatant was discarded. This procedure was repeated two additional times. The ®nal pellet was resuspended in 50 mM Tris-HCl buer (pH=8 at 378C). 
Binding assays

Enzyme assays
All enzymatic activities were determined by spectrophotometric methods using an Hitachi 1 UV-3000 spectrophotometer and were shown to be linear in the tissue and protein concentration range used. The determination of monoamine oxidase (EC 1.4.3.4) activity was performed according to the method of Bembenek et al. (1990) using kynuramine as a substrate and monitoring the formation of 4-hydroxyquinoline at 316 nm. Cytochrome c oxidase (EC 1.9.3.1) activity was assayed at 378C according to the method of Rustin et al. (1994) by monitoring the oxidation of ferrocytochrome c (prepared from type III horse heart cytochrome c (Sigma) at 550 nm and NADPH cytochrome c reductase (EC 1.6.2.5) was assayed at room temperature as described by Graham (1993) .
Immunocytochemistry
Cryosections from adult rat liver were ®xed in 100% methanol for 10 min. Sections were incubated for 48 h at 48C with two primary antibodies: s 1 receptor rabbit polyclonal antibody (diluted 1 : 200) (Alonso et al., 2000) and a mouse monoclonal antibody against the mitochondrial market protein Ab-1 (clone 113-1) (from Lab Vision Corporation, www.labvision.com, Cat No.: MS-627-p1). The Ab-1 antibody was used at a 1 : 100 dilution. Sections were rinsed in PBS three times and incubated for 2 h with two secondary antibodies, FITC-goat anti-rabbit IgG (Zymed, 1 : 150) and rhodamine Red-X-conjugated Anipure goat anti-mouse IgG (Jackson Labs, 1 : 150). Antibodies were diluted in PBS containing 0.1% gelatin, 0.1% Triton X-100 and 1% normal goat serum. The slides were then mounted with the Prolong Antifade Kit (Molecular Probes Inc.) and observed under Olympus Fluoview laser scanning microscope. 
Drugs
Data analysis
Equilibrium, namely K d (dissociation constant) and B max (maximal density of binding sites), and inhibition (IC 50 ) binding parameters were calculated by means of a non-linear regression method using a commercially available software (Micropharm, INSERM 1990; Urien, 1995) by modelling the data to one or two component models according to Hill equations as described previously .
A Hill coecient (nH) value equal one corresponds to a competitive interaction and thus indicates the presence of one class of binding sites. In this case, inhibition constants (K i ) were calculated from the IC 50 values according to the method of Cheng & Pruso (1973) . All data are presented as the mean+s.e.mean of three or more individual experiments.
Results
Characterization of purified mitochondria
Given that s binding sites were described to be highly enriched in liver and brain microsomes (McCann et al., 1994; Dehaven-Hudkins et al., 1994) , we evaluated the possible contamination of our mitochondrial preparations by microsomal membranes. Thus, liver and brain mitochondria were characterized for purity for their content in monoamine oxidase (an outer mitochondrial membrane marker), cytochrome c oxidase (an inner mitochondrial membrane marker) and the microsomal marker, NADPH cytochrome c reductase and compared to the respective microsomal fractions. A high activity of the two mitochondrial markers was found in the mitochondrial fractions whereas NADPH cytochrome c reductase activity was very low and not detectable in puri®ed liver and brain mitochondria, respectively (Table 1) .
These results indicate that our puri®ed mitochondrial fractions were devoid of microsomes and thus were appropriate to use in search of mitochondrial s binding sites. These preparations corresponded to those previously described using the same mitochondrial puri®cation procedures (Sims, 1990; Morin et al., 1998 (Quirion et al., 1992; Hellewell et al., 1994) . Figure 1A shows that [ 3 H](+)-pentazocine binds to liver mitochondria and reached equilibrium after 90 min incubation at 378C. When intact mitochondria were used a non-saturable binding component was observed ( Figure 1B) . It was eliminated when mitochondria were subjected to hypo-osmotic shock and sonication ( Figure 1A ). This component probably corresponds to an uptake mechanism, which accumulates the ligand within the mitochondria without binding. Therefore all the following experiments were performed on broken mitochondria. Dilution of the suspension (1/100) induced a slow dissociation of the ligand from its binding sites demonstrating that the binding was reversible ( Figure  1C Figure 2 .
In order to con®rm the nature of the sites labelled by The K i value for (+)-pentazocine was slightly higher than the K d value determined from equilibrium experiments (2.42+0.50 nM) but it is probably due to the use of the (+)-pentazocine radioligand which has higher anity than the racemic compound (Bowen et al., 1989; Quirion et al., 1992) . Opipramol, ifenprodil, carbetapentane, DTG and amiodarone were found to be very potent inhibitors (K i 5100 nM) of [ 3 H](+)-pentazocine binding whereas progesterone and testosterone showed moderate inhibition with K i values around 1 mM. The other steroids hormones were less active with K i values higher than 4 mM.
The rank order of potency at the [ 3 H](+)-pentazocine binding sites is similar between the liver mitochondria and the well-characterized brain membranes (Cagnotto et al., 1994; Dehaven-Hudkins et al., 1994; McCann et al., 1994 ; Table 2 ) showing a strong correlation (r=0.975, P50.0001; Figure 4) . A similar relation was found between liver mitochondria and liver microsomes (r=0.966; P50.0001; 
Sub-mitochondrial location of [ 3 H](+)-pentazocine binding sites
The sub-mitochondrial localization of [ 3 H](+)-pentazocine binding sites was determined using a digitonin solubilization protocol to separate the outer from the inner mitochondrial membrane as described by Anholt et al. (1986) . Intact liver mitochondria were incubated with a low digitonin concentration (0.6 mg digitonin mg 71 protein), which resulted in the extraction of monoamine oxidase (an outer membrane marker) without aecting cytochrome c oxidase activity (an inner membrane marker, Figure 5 ), con®rming previous results (Anholt et al., 1986; Morin et al., 1998) . Under these conditions, [ 
Immunostaining for s 1 receptors of liver mitochondria
In order to con®rm the presence of s receptors on mitochondria, liver sections were double immunostained for s 1 receptors and a mitochondria marker (mitochondria Ab-1 primary antibody). Using conventional immuno¯uorescence the presence of s 1 receptor (green) and mitochondria Ab-1 (red) in rat liver was clear (Figure 6 ). When confocal images of s 1 receptor staining and mitochondria Ab-1 staining were merged, a colocalization (yellow) of their respective antigens was observed. compared to the liver. Inhibition experiments con®rmed this dierence as all the s compounds tested were less potent when tested on brain than on liver mitochondria (Table 2 ). In addition, the selective antagonist rimcazole was without eect ( Table 2 ). The only notable exceptions were steroid hormones, which exhibit the same anities in both liver and brain mitochondria preparations.
Discussion
During the past few years s 1 recognition sites have been extensively studied. These studies were almost exclusively carried out on microsomal and plasma membranes because s 1 recognition sites are more abundant in these cellular fractions whatever the organ studied. However, several observations have suggested that these sites could be also present on other organelles (Cagnotto et al., 1994; DehavenHudkins et al., 1994; Alonso et al., 2000) but no clear demonstration and pharmacological characterization using puri®ed preparations were performed. In the present study, we demonstrate the presence of [ 3 H](+)-pentazocine binding sites on puri®ed preparation of mitochondria and provide the pharmacological pro®le of these mitochondrial binding sites, which proves their similarity with s 1 receptors.
In liver mitochondria, [ 3 H](+)-pentazocine labels one class of high anity (K d =3 nM) binding sites, similar to that observed in synaptic membranes (Dehaven-Hudkins et al., 1994; Nguyen et al., 1996) . The mitochondrial sites also display high anity for other s 1 ligands such as haloperidol, opipramol, ifenprodil or carbetapentane. The binding inhibition pro®le obtained with these reference compounds is Table 2 . Regression line was obtained by least squares ®t analysis of the data points. (Su et al., 1988; Schwarz et al., 1989; Bergeron et al., 1999) H](+)-pentazocine and typical s 1 ligands display lower anities for these sites. For example, haloperidol is 700-fold less potent on brain than on liver mitochondria and opipramol, ifenprodil and carbetapentane were ineective on the former. This indicates that mitochondrial brain sites dier from the liver ones and from the typical peripheral s 1 receptors. In addition, they do not appear to be related to s 2 receptors because the s 2 binding ligand DTG showed a moderate anity for these sites (K i =0.6 mM). Although these sites are distinct from s 1 , they exhibit common binding recognition properties for steroid hormone ligands and the antisteroid agent tamoxifen, which have similar anities for liver and brain mitochondrial [ In support of our binding data, double¯uorescence studies, using both an anti-s 1 antibody (Alonso et al., 2000) and a mitochondrial marker, clearly show the presence of immunoreactive s 1 protein(s) on liver mitochondrial membranes.
The pharmacological signi®cance of these binding sites is unknown. The same comment can be made for the s receptors. Indeed, although numerous pharmacological eects have been associated with s 1 receptors (reviewed by Matsuno & Mita, 1998; Maurice et al., 1999; Bowen, 2000) , the cellular transduction mechanism and the functional role of these receptors remain unclear. Among the eects described, s ligands exert cytoprotective and more particularly neuroprotective properties (Maurice & Lockhart, 1997) . This function of the ligands relates to their ability to directly inhibit the excitatory neurotransmitter system (Maurice & Lockhart, 1997) . More recently, several lines of evidence indicated that s receptors could mediate some of their eects by altering intracellular eects. For example, they were shown to modulate intracellular calcium and more particularly facilitate the mobilization of intracellular calcium pools (Hayashi et al., 2000) . This increase, due to the release of calcium from endoplasmic reticulum stores, has been suggested to contribute to the cytoprotective eect, reducing indirectly presynaptic glutamate release (Maurice & Lockhart, 1997) . These data indicate that s ligands might use calcium signal as cellular transduction mechanism and may participate to the control of cellular calcium homeostasis. Since mitochondria are known to store calcium (Gunter et al., 1994) and are supposed to play a role in the transduction of the calcium signal (Ichas et al., 1997) we can speculate that mitochondrial [ A possible relationship between s receptors and sterol metabolism has also been evoked. Indeed, the s 1 receptor has been cloned in several species (Hanner et al., 1996; Kekuda et al., 1996; Seth et al., 1997) and shows a 30% identity and a 60% homology to a yeast sterol C8-C7 isomerase suggesting a role for this drug-binding protein in sterol synthesis (Moebius et al., 1997) . In addition, certain neurosteroids have been shown to exhibit modulatory eects via s receptors (Monnet et al., 1995; Bergeron et al., 1996) . Interestingly, another drug-receptor, the peripheral-type benzodiazepine receptor, is precisely localized on the outer mitochondrial membrane where it is involved in the transport of cholesterol into mitochondria, the ®rst step in steroid biosynthesis (Papadopoulos et al., 1997; Li et al., 2001) . Although the role of peripheral-type benzodiazepine receptors in cholesterol transport into mitochondria of steroidogenic cells has been shown, it is important to note that a more general role for this ubiquitous receptor protein in intracellular cholesterol compartmentalization has been proposed (Li & Papadopoulos, 1998) . The recent ®nding that this receptor is a highanity cholesterol binding protein Lacapere et al., 2001 ) further supports its function in cholesterol compartmentalization.
Given that our data demonstrate that [ 3 H](+)-pentazocine binding sites are also located on the outer membrane of mitochondria and are modulated by several steroid hormones, especially progesterone which is considered to be a putative endogenous ligand (Su et al., 1988; Schwarz et al., 1989; Bergeron et al., 1999) , a possible modulation of steroid biosynthesis and/or cholesterol movement across mitochondrial membrane, initial step in membrane biogenesis and steroid biosynthesis, by s ligands cannot be excluded. This might also contribute to the cytoprotective eect of these drugs. Although the role of s 1 receptors has not yet been de®ned, their involvement in this process seems plausible. The eect of steroids and Ca 2+ on s 1 receptors together with their presence on the mitochondrial membranes, presented herein, support this hypothesis. Studies to test these hypotheses are in progress in our laboratory. In conclusion, we report herein the presence and the pharmacological characteristics of mitochondrial s 1 binding sites. The assignment of these drug-binding sites to mitochondria, considering the vital role of these organelles in respiration, apoptosis, sterol metabolism etc, opens a new area for the application of s 1 drug ligands in search of a role of this drug-binding protein.
